ACRV
Acrivon Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Acrivon Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Acrivon Therapeutics, Inc.
1.67
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $21.8M | 57.14% | +46.63% | |
| 2 | Sands Capital VenturesSands Capital Ventures | $4.1M | 10.70% | +7.85% | |
| 3 | Acadian Asset ManagementAcadian | $2.1M | 5.44% | +37.73% | |
| 4 | Vanguard Capital ManagementVanguardindex-like | $1.7M | 4.45% | +31.85% | |
| 5 | Wellington Management GroupWellington | $1.6M | 4.15% | 0.00% | |
| 6 | Renaissance TechnologiesRenaissance Technologies | $1.4M | 3.55% | +0.06% | |
| 7 | Two Sigma InvestmentsTwo Sigma | $1.1M | 3.00% | +64.74% | |
| 8 | Marshall WaceMarshall Wace | $946,704 | 2.49% | −5.10% | |
| 9 | Bridgeway Capital ManagementBridgeway | $674,442 | 1.77% | +138.45% | |
| 10 | Geode Capital ManagementGeodeindex-like | $472,273 | 1.24% | +12.20% | |
| 11 | BlackRockBlackRockindex-like | $425,620 | 1.12% | +14.44% | |
| 12 | GSA Capital PartnersGSA Capital Partners | $357,000 | 0.94% | +7.34% | |
| 13 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $327,748 | 0.86% | +71.24% | |
| 14 | XTX TopcoXTX Topco | $317,265 | 0.83% | +166.50% | |
| 15 | Jane Street GroupJane Street | $132,874 | 0.35% | −68.86% | |
| 16 | Northern TrustNorthern Trustindex-like | $119,620 | 0.31% | +37.42% | |
| 17 | State StreetState Streetindex-like | $119,518 | 0.31% | 0.00% | |
| 18 | UBS GroupUBS | $78,053 | 0.20% | +26.61% | |
| 19 | Citadel AdvisorsCitadel | $73,471 | 0.19% | new | |
| 20 | Dimensional Fund AdvisorsDimensional | $52,212 | 0.14% | +59.73% | |
| 21 | Spark Investment ManagementSpark | $50,374 | 0.13% | new | |
| 22 | Springbok Capital ManagementSpringbok | $42,747 | 0.11% | 0.00% | |
| 23 | Bank of AmericaBank of America | $29,204 | 0.08% | −0.64% | |
| 24 | Verdad AdvisersVerdad | $26,796 | 0.07% | new | |
| 25 | Goldman Sachs GroupGoldman Sachs | $26,558 | 0.07% | +1.21% |
45 managers report $38.1M of Acrivon Therapeutics on form 13F for the quarter ended Jun 30 '26. 5 of them hold 80% of it; RA Capital Management is largest at 57.14%.
Linked news
NewsNo implied move.
No implied move.
Expected move
No implied move.